Buckley Wealth Management LLC Sells 870 Shares of Bristol-Myers Squibb (NYSE:BMY)

Buckley Wealth Management LLC lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 5.2% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 15,732 shares of the biopharmaceutical company’s stock after selling 870 shares during the period. Buckley Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $853,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Northwest Financial Advisors bought a new stake in Bristol-Myers Squibb during the fourth quarter valued at about $27,000. Pacific Capital Wealth Advisors Inc. bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth about $34,000. VisionPoint Advisory Group LLC boosted its stake in shares of Bristol-Myers Squibb by 300.5% in the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 553 shares during the period. Turtle Creek Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth about $40,000. Finally, Wetzel Investment Advisors Inc. bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth about $40,000. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BMY. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Wells Fargo & Company boosted their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Finally, BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Trading Up 1.1 %

Shares of NYSE BMY traded up $0.46 during midday trading on Friday, hitting $41.97. The company’s stock had a trading volume of 6,467,179 shares, compared to its average volume of 15,646,365. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The business’s 50 day moving average is $43.25 and its two-hundred day moving average is $48.27. Bristol-Myers Squibb has a 12-month low of $39.63 and a 12-month high of $65.38. The firm has a market cap of $85.08 billion, a P/E ratio of -13.59, a price-to-earnings-growth ratio of 14.54 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the prior year, the business posted $2.05 earnings per share. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. As a group, equities research analysts expect that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be paid a $0.60 dividend. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 5.72%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.